ASCO Proceedings
BREAST CANCER—TRIPLE-NEGATIVE/CYTOTOXICS/LOCAL THERAPY LBA1000 Oral Abstract Session, Tue, 9:45 AM-12:45 PM NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose- dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. Sandra M. Swain, Gong Tang, Charles E. Geyer, Priya Rastogi, James Norman Atkins, Paul P. Donnellan, Louis Fehrenbacher, Catherine A. Azar, Andre Robidoux, Jonathan Polikoff, Adam Brufsky, David D. Biggs, Edward A. Levine, John L. Zapas, Louise Provencher, Edith A. Perez, Soonmyung Paik, Joseph P. Costantino, Eleftherios P. Mamounas, Norman Wolmark; National Surgical Adjuvant Breast and Bowel Project and Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC; NSABP Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and University of Texas, Southwestern Medical Center, Dallas, TX; National Surgical Adjuvant Breast and Bowel Project and University of Pittsburgh Cancer Institute, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and SCCC-CCOP, Goldboro, NC; All Ireland Cooperative Oncology Research Group and University Hospital Galway, Galway, Ireland; National Surgical Adjuvant Breast and Bowel Project and Kaiser Permanente Northern California, Vallejo, CA; National Surgical Adjuvant Breast and Bowel Project and Kaiser Permanente, Denver, CO; National Surgical Adjuvant Breast and Bowel Project and Centre Hospitalier de l’Universite de Montreal, Montreal, QC, Canada; National Surgical Breast and Bowel Project and Kaiser Permanente Southern California, San Diego, CA; National Surgical Adjuvant Breast and Bowel Project and University of Pittsburgh, Magee-Womens Hospital, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and Helen F.
[Show full text]